To appraise the clinical and cost effectiveness of dapagliflozin and empagliflozin within their marketing authorisation for treating type 1 diabetes.
 
Status Proposed
Process STA
ID number 1217

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
07 November 2017 Scoping workshop
19 September 2017 - 17 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance